Details for New Drug Application (NDA): 218979
NDA 218979 describes KLOR-CON, which is a drug marketed by Upsher Smith Labs and Twi Pharms and is included in five NDAs. It is available from five suppliers. Additional details are available on the KLOR-CON profile page.
The generic ingredient in KLOR-CON is potassium chloride. There is one drug master file entry for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
The generic ingredient in KLOR-CON is potassium chloride. There is one drug master file entry for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the potassium chloride profile page.
Summary for 218979
| Tradename: | KLOR-CON |
| Applicant: | Twi Pharms |
| Ingredient: | potassium chloride |
| Patents: | 0 |
Pharmacology for NDA: 218979
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption |
Suppliers and Packaging for NDA: 218979
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| KLOR-CON | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 218979 | ANDA | Upsher-Smith Laboratories, LLC | 0245-0835 | 0245-0835-01 | 10 BLISTER PACK in 1 CARTON (0245-0835-01) / 10 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK |
| KLOR-CON | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 218979 | ANDA | Upsher-Smith Laboratories, LLC | 0245-0835 | 0245-0835-11 | 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0245-0835-11) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 8MEQ | ||||
| Approval Date: | Oct 28, 2024 | TE: | AB2 | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 10MEQ | ||||
| Approval Date: | Oct 28, 2024 | TE: | AB2 | RLD: | No | ||||
Complete Access Available with Subscription
